Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01726517
Other study ID # GS-US-337-0118
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2012
Est. completion date January 2014

Study information

Verified date November 2014
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV), administered for 8 or 12 weeks of treatment in participants with chronic genotype 1 hepatitis C virus (HCV) infection who are treatment-naive, and for 12 weeks in participants who had previously received a regimen containing a protease inhibitor for the treatment of HCV.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 2014
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years, with chronic genotype 1 HCV infection

- HCV RNA equal to or greater than 10,000 IU/mL at screening

- Cirrhosis determination; a liver biopsy may be required

- Screening laboratory values within defined thresholds

- Use of two effective contraception methods if female of childbearing potential or sexually active male

Exclusion Criteria:

- Pregnant or nursing female or male with pregnant female partner

- Current or prior history of clinical hepatic decompensation

- Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)

- Chronic use of systemic immunosuppressive agents

- History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

Study Design


Intervention

Drug:
LDV/SOF
LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
RBV
RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and = 75 kg = 1200 mg)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) 12 weeks after stopping study treatment. Posttreatment Week 12
Primary Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s) The number of participants experiencing an adverse event leading to permanent discontinuation of study drug(s) was summarized. Baseline to Week 12
Secondary Percentage of Participants With SVR at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24) SVR2, SVR4, SVR8, and SVR24 was defined as HCV RNA < LLOQ at 2, 4, 8, and 24 weeks following the last dose of study drug, respectively. Posttreatment Weeks 2, 4, 8, and 24
Secondary Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse Viral breakthrough was defined as HCV RNA = LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.
Viral relapse was defined as HCV RNA = LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.
Baseline to Posttreatment Week 24
See also
  Status Clinical Trial Phase
Withdrawn NCT02806362 - Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Phase 3
Completed NCT01701401 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV Phase 3
Withdrawn NCT01691235 - SIMpill Medication Dispensing Device in the Treatment of HCV N/A
Completed NCT02945228 - Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
Completed NCT01740791 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection Phase 1
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT01851330 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3) Phase 3
Completed NCT01852604 - Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) Phase 2
Completed NCT02105467 - Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) Phase 3
Recruiting NCT02038387 - Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD) N/A
Completed NCT01581138 - VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C Phase 2
Completed NCT02629172 - Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
Completed NCT01768286 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection Phase 3
Completed NCT01686789 - Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 Phase 4
Completed NCT00610597 - Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease N/A
Completed NCT02707952 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection Phase 3
Completed NCT01516918 - A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis Phase 2
Completed NCT02723084 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection Phase 3